Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 16;17(6):e86116.
doi: 10.7759/cureus.86116. eCollection 2025 Jun.

Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management

Daniel Herrero Rivera  1   2 , María Soriano Segura  1 , Javier Orlando Prato Varela  1 , Yaroslav Brygadyr Medvid  3 , José Antonio López Martín  4
Affiliations
Case Reports

Complete Remission With Fourth-Line Immunotherapy After Chemotherapy Failure in a Lung Cancer Patient With Severe Autoimmune Disease: An Unexpected Turn in Oncologic Management

Daniel Herrero Rivera et al. Cureus. .

Abstract

The indication for nivolumab in patients with advanced non-small cell lung cancer (NSCLC) who have progressed to first-line platinum-based systemic therapy was one of the first indications for immunotherapy approved by regulatory agencies. However, it is generally the case that patients with autoimmune diseases (AIDs) are excluded from studies due to the risk of immune exacerbations and a higher rate of immune-related adverse effects. This deprives these patients of the potential benefits they could obtain from immunotherapy, especially in those cases with favorable biomarkers of a good response. In this study, we present a clinical case of a patient with rapidly progressive multiple sclerosis (MS) of years of evolution, who obtained an impressive response to immunotherapy as a last therapeutic option, remaining cancer-free to date.

Keywords: autoimmune disease; complete response; immune related adverse events; immunotherapy; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Daniel Herrero Rivera declare(s) Support for attending meetings and/or travel from Bristol Myers Squibb, Ipsen, Lilly, Roche. Daniel Herrero Rivera declare(s) personal fees from AstraZeneca, Pfizer and Roche. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. CT scan on September 27, 2022, showing mass of 5 x 4 cm in lower left lobe (red arrow)
This image corresponds to the primary tumor before being operated on.
Figure 2
Figure 2. Histological section showing adenocarcinoma of solid and papillary pattern
A) Microscopic (histological) examination: Histologically, the lesion was a neoplasm of epithelial origin, composed of atypical cuboidal or columnar cells with oval nuclei, irregular nuclear membranes, prominent nucleoli, and eosinophilic or clear cytoplasm. These cells were predominantly arranged in solid nests (solid pattern: 80%) or around fibrovascular cores (papillary/micropapillary pattern: 20%). The tumor showed involvement of the visceral pleura (PL2), with no clear evidence of lymphovascular invasion, perineural invasion, or STAS. No lymph nodes were submitted with the specimen. Immunohistochemical study: On immunohistochemical analysis, the tumor cells were positive for TTF-1 and napsin-A, and negative for p63, consistent with a diagnosis of primary lung adenocarcinoma. B) An additional immunohistochemical study for PD-L1 (PD-L1 22C3, DAKO) showed positivity in the majority of tumor cells (TPS: 90%). Final pathological diagnosis: High-grade (G3) pulmonary adenocarcinoma STAS: Spread through air spaces; TPS: Tumor proportion score
Figure 3
Figure 3. December 2023 CT scan showing disease progression with new hepatic lesions
This image corresponds to the appearance of new metastatic liver lesions after receiving three cycles of pemetrexed. The red arrow corresponds to a new 13-mm metastatic lesion in segment III.
Figure 4
Figure 4. June 2024 CT scan showing complete response of hepatic lesions
This image corresponds to the same plane as in Figure 3, with the disappearance of metastatic liver lesions after receiving 12 cycles of nivolumab.
See this image and copyright information in PMC

References

    1. Immunotherapy in patients with autoimmune disease. Rakshit S, Molina JR. J Thorac Dis. 2020;12:7032–7038. - PMC - PubMed
    1. Safety and efficacy of immune checkpoint inhibitors in cancer patients and preexisting autoimmune disease: a systematic review and meta-analysis in non-small-cell lung cancer. Aung WY, Lee CS, Morales J, Rahman H, Seetharamu N. http://www.sciencedirect.com/science/article/pii/S1525730423001080. Clin Lung Cancer. 2023;24:598–612. - PubMed
    1. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies. Xie W, Huang H, Xiao S, Fan Y, Deng X, Zhang Z. Autoimmun Rev. 2020;19:102687. - PubMed
    1. Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047) Asao T, Shukuya T, Uemura K, et al. Lung Cancer. 2024;194:107894. - PubMed
    1. Are patients with autoimmune disorders eligible for immunotherapy? Madama D, Pego A. Pulmonology. 2021;27:264–266. - PubMed

Publication types

LinkOut - more resources